Trial Profile
A Phase Ib, Open-Label, Multicenter Study of the Safety and Pharmacokinetics of the Combination of RhuMab 2C4 (Omnitarg), a Recombinant Humanized Antibody to HER2, and Docetaxel (Taxotere) in Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Pertuzumab (Primary) ; Docetaxel
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Roche
- 24 Nov 2015 Protocol has been amended in time frame of primary endpoint from 4 weeks to approx. 10 months to upto day 15.
- 07 Jul 2015 New trial record